Scientists test 'Booster Pill' to supercharge Cancer-Fighting cells
NCT ID NCT05044039
Summary
This study is testing if taking an oral drug called duvelisib after receiving CAR-T cell therapy can help the engineered immune cells survive longer in the body and work better. It will involve about 42 adults with certain types of lymphoma or leukemia who are already scheduled to get CAR-T therapy. The main goal is to see if this combination is safe and if it can reduce severe side effects while improving the cancer treatment's effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.